Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10<sup>®</sup> to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10<sup>®</sup> to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies

<b>Background</b>. Monitoring of biological TNF inhibitors is a very important tool to guide clinical decisions using specialized algorithms, especially in gastroenterology. A new chemiluminescent instrument (i-TRACK<sup>10®</sup> from Theradiag) could replace ELISA technique...

Full description

Bibliographic Details
Main Authors: Anne Emmanuelle Berger, Aude Gleizes, Louis Waeckel, Xavier Roblin, Roman Krzysiek, Salima Hacein-Bey-Abina, Alessandra Soriano, Stephane Paul
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:International Journal of Molecular Sciences
Subjects:
TNF inhibitors
adalimumab
infliximab
therapeutic drug monitoring
anti-drug antibodies
CLIA
Online Access:https://www.mdpi.com/1422-0067/23/17/9561

Internet

https://www.mdpi.com/1422-0067/23/17/9561

Similar Items